While reporting financial results for the fourth quarter on Friday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings and revenue growth guidance for the full-year 2024.
For fiscal 2024, the company now projects adjusted earnings in a range of $7.10 to $7.40 per share on a worldwide total revenue growth in the low single-digits.
On average, 23 analysts polled by Thomson Reuters expect the company to report earnings of $7.00 per share on revenues growth of 1.9 percent to $45.58 billion for the year. Analysts' estimates typically exclude special items.
For the fourth quarter, the company reported net income attributable to Bristol-Myers Squibb of $1.76 billion or $0.87 per share, lower than $2.02 billion or $0.95 per share in the prior-year quarter. Excluding items, adjusted net earnings per share for the quarter was $1.70, compared to last year's $1.82.
Total revenues for the quarter declined 1 percent to $11.48 billion from $11.41 billion in the same quarter last year.
Analysts expected quarterly earnings of $1.53 per share on revenues of $11.19 billion for the quarter.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.